Niven Mehra

9.0k total citations · 4 hit papers
178 papers, 4.4k citations indexed

About

Niven Mehra is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Niven Mehra has authored 178 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Pulmonary and Respiratory Medicine, 103 papers in Oncology and 51 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Niven Mehra's work include Prostate Cancer Treatment and Research (126 papers), Radiopharmaceutical Chemistry and Applications (51 papers) and PARP inhibition in cancer therapy (39 papers). Niven Mehra is often cited by papers focused on Prostate Cancer Treatment and Research (126 papers), Radiopharmaceutical Chemistry and Applications (51 papers) and PARP inhibition in cancer therapy (39 papers). Niven Mehra collaborates with scholars based in Netherlands, United States and United Kingdom. Niven Mehra's co-authors include Johann S. de Bono, Fred Saad, Karim Fizazi, Oliver Sartor, Neal D. Shore, Joaquı́n Mateo, Emile E. Voest, Antoine Thiery-Vuillemin, Jinyu Kang and Shahneen Sandhu and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Niven Mehra

167 papers receiving 4.3k citations

Hit Papers

Olaparib for Metastatic Castration-Resistant Prostate Cancer 2020 2026 2022 2024 2020 2021 2023 2023 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib for Metastatic Castration-Resistant Prostate Cancer
    2020 1.4k citations Johann S. de Bono, Joaquı́n Mateo et al. New England Journal of Medicine profile →
  2. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
    2021 183 citations Johann S. de Bono, Niven Mehra et al. profile →
  3. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
    2023 132 citations Fred Saad, Neal D. Shore et al. profile →
  4. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
    2023 92 citations Bastiaan M. Privé, Steffie M. B. Peters et al. European Journal of Nuclear Medicine and Molecular Imaging profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Niven Mehra Netherlands 31 2.6k 2.3k 1.5k 1.3k 775 178 4.4k
Antoine Thiery-Vuillemin France 24 2.4k 0.9× 2.0k 0.8× 1.2k 0.8× 985 0.8× 449 0.6× 155 3.7k
Przemyslaw Twardowski United States 29 2.4k 0.9× 2.2k 0.9× 1.6k 1.0× 1.2k 1.0× 464 0.6× 113 4.3k
Joaquı́n Mateo United Kingdom 34 3.2k 1.2× 3.3k 1.4× 2.1k 1.4× 1.8k 1.4× 742 1.0× 148 6.1k
Dana E. Rathkopf United States 35 3.8k 1.5× 1.7k 0.7× 1.6k 1.1× 1.4k 1.1× 1.3k 1.6× 203 5.3k
Florence Dalenc France 33 1.6k 0.6× 2.6k 1.1× 1.3k 0.9× 1.3k 1.0× 428 0.6× 209 4.5k
Arlene Chan Australia 30 2.3k 0.9× 5.4k 2.3× 1.8k 1.2× 1.7k 1.3× 1.1k 1.5× 144 6.8k
Vandana G. Abramson United States 34 1.3k 0.5× 2.7k 1.2× 1.4k 0.9× 1.2k 0.9× 1.2k 1.5× 119 4.9k
Michael T. Schweizer United States 33 2.2k 0.8× 1.1k 0.5× 929 0.6× 746 0.6× 444 0.6× 144 3.1k
Agnieszka Jagiełło-Gruszfeld Poland 13 2.4k 0.9× 3.4k 1.5× 1.9k 1.2× 1.3k 1.0× 881 1.1× 60 5.4k
Arun Azad Australia 38 4.6k 1.8× 2.0k 0.8× 1.4k 0.9× 2.1k 1.6× 1.6k 2.0× 261 6.1k

Countries citing papers authored by Niven Mehra

Since Specialization
Citations

This map shows the geographic impact of Niven Mehra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niven Mehra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niven Mehra more than expected).

Fields of papers citing papers by Niven Mehra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niven Mehra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niven Mehra. The network helps show where Niven Mehra may publish in the future.

Co-authorship network of co-authors of Niven Mehra

This figure shows the co-authorship network connecting the top 25 collaborators of Niven Mehra. A scholar is included among the top collaborators of Niven Mehra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niven Mehra. Niven Mehra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Dijk, Nick van, Daniël J. Vis, Bram van den Broek, et al.. (2025). Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial. European Journal of Cancer. 229. 115731–115731.
3.
Robbrecht, Debbie, John W.M. Martens, Maureen J.B. Aarts, et al.. (2025). Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis. European Urology Oncology. 9(1). 7–11. 1 indexed citations
4.
Mehra, Niven, Jens Voortman, David R. Wise, et al.. (2024). Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). TPS2672–TPS2672. 4 indexed citations
5.
Wilpe, Sandra van, Martijn H. den Brok, Harm Westdorp, et al.. (2024). Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Annals of Oncology. 35(12). 1126–1137. 14 indexed citations
6.
Mehra, Niven, André N. Vis, Joyce M. van Dodewaard-de Jong, et al.. (2023). The conundrum of treating metastatic hormone sensitive prostate cancer. European Urology Open Science. 57. S161–S161.
7.
Basten, Jean‐Paul A. van, Pieter L. van den Berg, Roderick CN van den Bergh, et al.. (2023). TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment. BMJ Open. 13(8). e072572–e072572. 1 indexed citations
8.
Privé, Bastiaan M., Steffie M. B. Peters, Yvonne H. W. Derks, et al.. (2023). Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. European Journal of Nuclear Medicine and Molecular Imaging. 50(7). 1906–1918. 92 indexed citations breakdown →
9.
Tolmeijer, Sofie H., et al.. (2023). Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?. Critical Reviews in Clinical Laboratory Sciences. 61(3). 178–204. 5 indexed citations
10.
Tolmeijer, Sofie H., Takayuki Sumiyoshi, Edmond M. Kwan, et al.. (2023). Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(15). 2835–2844. 26 indexed citations
11.
Weerd, Vanja de, Jaco Kraan, John W.M. Martens, et al.. (2023). Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer. JCO Precision Oncology. 7(7). e2300156–e2300156. 1 indexed citations
12.
Oort, Inge M. van, et al.. (2023). Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer. Cancers. 15(10). 2814–2814. 8 indexed citations
13.
Tolmeijer, Sofie H., Sandra van Wilpe, Maartje J. Geerlings, et al.. (2023). Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer. European Urology Oncology. 7(2). 282–291. 10 indexed citations
14.
Richters, Anke, Joost L. Boormans, Michiel S. van der Heijden, et al.. (2021). Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: A contemporary Dutch nationwide cohort study. European Urology Open Science. 33. S391–S391. 1 indexed citations
15.
Donders, Rogier, et al.. (2021). The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer. British Journal of Clinical Pharmacology. 88(3). 1170–1178. 7 indexed citations
16.
Creemers, Jeroen H. A., W. Joost Lesterhuis, Niven Mehra, et al.. (2021). A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. Journal for ImmunoTherapy of Cancer. 9(5). e002032–e002032. 15 indexed citations
17.
Smits, Minke, Inge M. van Oort, Winald R. Gerritsen, et al.. (2021). Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. British Journal of Cancer. 126(6). 907–916. 9 indexed citations
18.
Wilpe, Sandra van, Sofie H. Tolmeijer, Rutger H.T. Koornstra, et al.. (2021). Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. Cancers. 13(9). 2249–2249. 39 indexed citations
19.
Doelen, Maarten J. van der, Hans M. Westgeest, Carin A. Uyl‐de Groot, et al.. (2020). Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer. International Journal of Cancer. 148(2). 385–395. 26 indexed citations
20.
Bono, Johann S. de, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 382(22). 2091–2102. 1397 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antoine Thiery-Vuillemin Breakdown of academic impact, for papers by Przemyslaw Twardowski Breakdown of academic impact, for papers by Joaquı́n Mateo Breakdown of academic impact, for papers by Dana E. Rathkopf Breakdown of academic impact, for papers by Florence Dalenc Breakdown of academic impact, for papers by Arlene Chan Breakdown of academic impact, for papers by Vandana G. Abramson Breakdown of academic impact, for papers by Michael T. Schweizer Breakdown of academic impact, for papers by Agnieszka Jagiełło-Gruszfeld Breakdown of academic impact, for papers by Arun Azad
Rankless by CCL
2026